Compare CALC & MLEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CALC | MLEC |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | Cayman Islands |
| Employees | N/A | 72 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 6.5M |
| IPO Year | 2020 | N/A |
| Metric | CALC | MLEC |
|---|---|---|
| Price | $0.78 | $7.37 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 110.4K | 67.2K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.42 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | $2.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.21 |
| 52 Week High | $7.20 | $23.22 |
| Indicator | CALC | MLEC |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 43.13 |
| Support Level | $0.50 | $7.20 |
| Resistance Level | $0.93 | $11.71 |
| Average True Range (ATR) | 0.07 | 0.94 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 92.93 | 5.87 |
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.